33 / 46
4
t h
E u r o S c i C o n C o n f e r e n c e o n
Neurology & Neurological
Disorders
Neurology 2018
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
Page 95
Journal of Neurology and Neuroscience
ISSN: 2171-6625
T
he worldwide prevalence of stroke continues to rise despite recent successes in treating acute ischemic stroke. With limited
patient eligibility and associated risk of tissue plasminogen activator (tPA) and mechanical thrombectomy, new preventive
and therapeutic modalities are needed to stave the rising wave of stroke. Inflammation plays a key role in brain damage after
cerebral ischemia and novel therapies that target pro-inflammatory cells have demonstrated promise for treatment for stroke.
Partial MHC class II constructs have been shown to prevent and/or reverse clinical signs of various inflammatory diseases such
as experimental autoimmune encephalomyelitis, collagen-induced arthritis and experimental autoimmune uveitis, by reducing
the number and frequency of activated cells in the damaged CNS. Herein, we review the use of partial MHC class II constructs
as a novel treatment for ischemic stroke. These constructs have been shown to reduce infarct volume and neurological deficit in
various cerebral ischemia models in young adult and aging male and female mice. In addition, partial MHC class II constructs
were shown to reverse stroke-associated splenic atrophy and promote a protective M2 macrophage/microglia phenotype in the
CNS which contributes to tissue repair and recovery after stroke. By addressing remaining STAIR criteria, such as efficacy in large
animal models of stroke, these constructs will be prime candidates for clinical trials of acute ischemic stroke.
offnerva@ohsu.eduRecombinant T-cell receptor ligand 1000: a novel
therapeutic for stroke
Halina Offner
1, 2
1
VA Portland Health Care System, Portland, Oregon
2
Oregon Health & Science University Portland, Oregon
J Neurol Neurosci 2018, Volume: 9
DOI: 10.21767/2171-6625-C1-009